JPMorgan analyst Chris Schott raised the firm’s price target on Regeneron (REGN) to $950 from $850 and keeps an Overweight rating on the shares. The company’s Q4 sales were largely in line with expectations, the analyst tells investors in a research note. The firm upped estimates for Regeneron, saying Dupixent continues to exceed expectations and Eylea HD continues to ramp following the recent label and product enhancements. JPMorgan sees an attractive share setup for Regeneron.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $800 from $745 at Wells Fargo
- Regeneron price target raised to $769 from $768 at Morgan Stanley
- Balanced Risk/Reward Keeps Regeneron at Hold Amid Solid Fundamentals and Pipeline Uncertainty
- Regeneron’s Earnings Call: Growth Engines and Rising Costs
- Regeneron Pharmaceuticals: Robust 4Q25 Beat, Underappreciated Pipeline Upside, and 2026 Catalysts Support Buy Rating and $870 Target